RECRUITING

A Study of Breath Testing for Small Intestinal Bacterial Overgrowth

Conditions

Gastroesophageal Reflux Regurgitation Heartburn Proton pump inhibitor

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Researchers hope to determine how often small intestinal bacterial overgrowth occurs after taking proton pump inhibitors.

Official Title

Breath Testing for Small Intestinal Bacterial Overgrowth in Patients Treated With Proton Pump Inhibitors

Quick Facts

Study Start:2023-11-17

Study Completion:2024-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05976165

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Predominant symptoms of gastroesophageal reflux disease including heartburn, regurgitation * Subjects must be able to give appropriate informed consent	* Prior diagnosis of SIBO * Use of PPIs or H2R-anatagonstists in the prior 3 months * Major concomitant illness (renal, hepatic, rheumatologic or cardiovascular disease, or malignancy) * Antibiotic therapy within one month * Prior gastrointestinal surgery including esophageal, gastric, and small or large bowel surgery * Previously diagnosed irritable bowel syndrome or inflammatory bowel disease * Individuals who are pregnant or breast feeding * Patients with plans to become pregnant * Inability to take PPIs, including allergy/sensitivity

Inclusion Criteria

Exclusion Criteria

* Predominant symptoms of gastroesophageal reflux disease including heartburn, regurgitation
* Subjects must be able to give appropriate informed consent

* Prior diagnosis of SIBO
* Use of PPIs or H2R-anatagonstists in the prior 3 months
* Major concomitant illness (renal, hepatic, rheumatologic or cardiovascular disease, or malignancy)
* Antibiotic therapy within one month
* Prior gastrointestinal surgery including esophageal, gastric, and small or large bowel surgery
* Previously diagnosed irritable bowel syndrome or inflammatory bowel disease
* Individuals who are pregnant or breast feeding
* Patients with plans to become pregnant
* Inability to take PPIs, including allergy/sensitivity

Contacts and Locations

Principal Investigator

Andree Koop, MD

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic Florida

Jacksonville, Florida, 32224

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Andree Koop, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-17

Study Completion Date2024-12-31

Study Record Updates

Study Start Date2023-11-17

Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

Proton pump inhibitor

Additional Relevant MeSH Terms

Gastroesophageal Reflux
Regurgitation
Heartburn